Related content

Prognostic and therapeutic relevance of the IGF pathway in Ewing’s sarcoma patients

By Luijtgaarden A.   Versleijen-Jonkers Y.   Roeffen M.   Schreuder H.   Flucke U.   Graaf W.  

Targeted Oncology, Vol. 8, Iss. 4, 2013-12 ,pp. : 253-260

Springer Publishing Company

Access to resources Recommend Favorite

Preclinical studies of treosulfan demonstrate potent activity in Ewing’s sarcoma

By Werner Sebastian   Mendoza Arnulfo   Hilger Ralf   Erlacher Miriam   Reichardt Wilfried   Lissat Andrej   Konanz Claudia   Uhl Marcus   Niemeyer Charlotte   Khanna Chand   Kontny Udo  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 1, 2008-06 ,pp. : 19-31

Springer Publishing Company

Access to resources Recommend Favorite

Therapy resistance mechanisms in Ewing’s sarcoma family tumors

By Ahmed Atif   Zia Hamid   Wagner Lars  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 657-663

Springer Publishing Company

Access to resources Recommend Favorite

Ewing’s Sarcoma of Mandible: A Very Rare Disease and Review of Indian Literature

By Sinha Deependra   Jha N.   Yadav Sanjay   Yadav Jitin   Sinha Rishav  

Indian Journal of Surgical Oncology, Vol. 5, Iss. 1, 2014-03 ,pp. : 81-84

Springer Publishing Company

Access to resources Recommend Favorite

Ezrin mediates growth and survival in Ewing’s sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway

By Krishnan Kartik   Bruce Ben   Hewitt Stephen   Thomas Dafydd   Khanna Chand   Helman Lee  

Clinical and Experimental Metastasis, Vol. 23, Iss. 3-4, 2006-06 ,pp. : 227-236

Springer Publishing Company

Access to resources Recommend Favorite